J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts.

J&J evaluated its Tremfya in patients with low body surface area moderate plaque psoriasis with special site involvement who had failed on topical treatment. “Special sites” include sensitive or highly visible areas affected by the disease including the scalp, face, skin folds and genitals, J&J explained in a release.